NCT03926624 2026-01-22Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageDelta-Fly Pharma, Inc.Phase 3 Terminated167 enrolled
NCT05201066 2026-01-07Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.NovartisPhase 2 Active not recruiting33 enrolled